Retatrutida
Triple agonist of GIP, GLP-1, and glucagon receptors developed by Eli Lilly. It is the first of its class to act on all three receptors simultaneously, resulting in weight loss superior to any other medication in clinical studies to date — up to 24% of body weight in 48 weeks.
Last updated:: 13/04/2026
Research Status
ANVISA (Brazil)
Not regulated
FDA (USA)
Under review
EMA (Europe)
Under review
Mechanism of Action
Retatrutide activates three hormonal receptors simultaneously: GLP-1 (suppresses appetite and stimulates insulin), GIP (potentiates the GLP-1 effect and improves lipid metabolism), and glucagon (increases energy expenditure and promotes hepatic lipolysis). This triple action creates a synergistic effect: GLP-1 reduces caloric intake, glucagon accelerates fat burning, and GIP amplifies both effects. The result is significantly greater weight loss than single (semaglutide) or dual (tirzepatide) agonists.
Study Protocols
Dosages and regimens used in published clinical studies. This does not constitute a medical prescription.
Obesidade / controle de peso
Subcutânea (SC)Dose de titulação inicial
Dose-alvo do estudo fase 2 (maior perda de peso: 24,2%)
Agonista triplo GIP/GLP-1/glucagon. Titulação de 4 em 4 semanas para minimizar efeitos gastrointestinais. Perda de peso média de 24,2% em 48 semanas na dose de 12 mg — a maior já registrada em ensaios clínicos. Ainda em fase 3 (programa TRIUMPH).
Benefits
Record weight loss
ProvenIn the TRIUMPH-2 study, participants lost up to 24.2% of body weight over 48 weeks at the 12 mg dose — the greatest weight loss ever recorded in clinical obesity trials.
View studyHepatic fat reduction (MASLD/NASH)
ProvenReduced hepatic fat by up to 86% in patients with hepatic steatosis. 93% of patients achieved complete steatosis resolution at the highest dose.
View studyImprovement of obstructive sleep apnea
Under researchOngoing phase 3 studies (TRIUMPH-3) are investigating efficacy in obesity-associated sleep apnea. Positive preliminary results from significant weight reduction.
Glycemic control in type 2 diabetes
ProvenReduced HbA1c by up to 2.2% over 36 weeks in the TRIUMPH-1 study, with 78% of patients reaching HbA1c < 5.7% (non-diabetic range).
View studyLipid profile improvement
ProvenSignificant reduction in triglycerides (-30 to -50%), LDL, and VLDL. Modest HDL increase. Cardiovascular benefit under investigation.
Risks and Side Effects
Nausea
Moderate(43-50% of patients)Most frequent side effect, mainly during titration. Generally transient and decreases after the first weeks at each dose.
Diarrhea
Low(25-35% of patients)Second most common gastrointestinal effect. Generally mild to moderate, resolves spontaneously.
Vomiting
Moderate(15-20% of patients)More common during titration phases. Reduced with slow titration and smaller meals.
Increased heart rate
Moderate(~10% of patients)Average increase of 2-4 bpm observed in studies. Effect of the glucagon component. Clinical significance is still being evaluated in cardiovascular outcome studies.
Pancreatitis
High(Rare (<1%))Class risk of GLP-1 agonists. Rare cases reported. Discontinue immediately if severe persistent abdominal pain occurs.
Muscle mass loss
Moderate(Common with rapid weight loss)Pronounced weight loss may include lean mass. Resistance exercise and adequate protein intake are recommended to mitigate this.
Internet vs. Science
What people say online compared to the actual scientific evidence.
Retatrutide causes 25% weight loss
Partially trueWhat they claim
It's the most powerful weight loss drug ever created, nearly as effective as bariatric surgery.
Actual evidence
The maximum mean loss was 24.2% over 48 weeks (12 mg dose). It is indeed the greatest weight loss in clinical trials, but individual results vary (5-35%). Bariatric surgery results in ~25-30% loss, so the comparison is plausible.
It's better than Ozempic and Mounjaro
Partially trueWhat they claim
Retatrutide is clearly superior to semaglutide and tirzepatide because it acts on 3 receptors.
Actual evidence
In non-comparative (cross-study) analysis, weight loss with retatrutide 12 mg (~24%) exceeded historical results for semaglutide 2.4 mg (~16%) and tirzepatide 15 mg (~21%). However, there is no direct head-to-head comparison study. Cross-study comparisons have methodological limitations.
Already available for purchase
FalseWhat they claim
You can buy retatrutide at compounding pharmacies or research suppliers.
Actual evidence
Retatrutide is still in phase 3 clinical trials. It has NOT been approved by the FDA, EMA, or ANVISA. Any sale is illegal and unregulated. Products sold as 'retatrutide research chemical' have no guarantee of purity or dosage.
Cures diabetes and hepatic steatosis
Partially trueWhat they claim
Retatrutide completely reverses type 2 diabetes and eliminates liver fat.
Actual evidence
The data are impressive: 78% of T2D patients reached non-diabetic HbA1c, and 93% had hepatic steatosis resolution. But 'cure' is imprecise — the effects depend on continued use. There are no long-term data on durability after discontinuation.
| Claim | O que dizem | Evidência real | Verdict |
|---|---|---|---|
| Retatrutide causes 25% weight loss | It's the most powerful weight loss drug ever created, nearly as effective as bariatric surgery. | The maximum mean loss was 24.2% over 48 weeks (12 mg dose). It is indeed the greatest weight loss in clinical trials, but individual results vary (5-35%). Bariatric surgery results in ~25-30% loss, so the comparison is plausible. | Partially true |
| It's better than Ozempic and Mounjaro | Retatrutide is clearly superior to semaglutide and tirzepatide because it acts on 3 receptors. | In non-comparative (cross-study) analysis, weight loss with retatrutide 12 mg (~24%) exceeded historical results for semaglutide 2.4 mg (~16%) and tirzepatide 15 mg (~21%). However, there is no direct head-to-head comparison study. Cross-study comparisons have methodological limitations. | Partially true |
| Already available for purchase | You can buy retatrutide at compounding pharmacies or research suppliers. | Retatrutide is still in phase 3 clinical trials. It has NOT been approved by the FDA, EMA, or ANVISA. Any sale is illegal and unregulated. Products sold as 'retatrutide research chemical' have no guarantee of purity or dosage. | False |
| Cures diabetes and hepatic steatosis | Retatrutide completely reverses type 2 diabetes and eliminates liver fat. | The data are impressive: 78% of T2D patients reached non-diabetic HbA1c, and 93% had hepatic steatosis resolution. But 'cure' is imprecise — the effects depend on continued use. There are no long-term data on durability after discontinuation. | Partially true |
Studies and References (4)
Rosenstock J, Frias J, Jastreboff AM, et al. — The Lancet (2024) — n=281
Redução de HbA1c de até 2,2% e perda de peso de até 16,9% em pacientes com DM2 em 36 semanas. 78% dos pacientes na dose mais alta atingiram HbA1c < 5,7%. Perfil de segurança consistente com a classe.
PubMedSanyal AJ, Kaplan LM, Frias JP, et al. — The Lancet (2024) — n=163
Redução de gordura hepática de até 86% em 48 semanas. 93% dos pacientes na dose 12 mg alcançaram resolução completa da esteatose (< 5% de gordura hepática por ressonância magnética). Melhora significativa dos marcadores de fibrose.
PubMedJastreboff AM, Kaplan LM, Frías JP, et al. — The Lancet (2023) — n=338
Perda de peso dose-dependente de até 24,2% em 48 semanas com retatrutida 12 mg (n=338). Efeitos colaterais predominantemente gastrointestinais. Primeiro estudo a demonstrar que agonismo triplo (GIP/GLP-1/glucagon) resulta em perda de peso significativamente maior que agentes anteriores.
PubMedJastreboff AM, Kaplan LM, Frías JP, et al. — New England Journal of Medicine (2023) — n=338
Análise complementar do estudo fase 2 publicada no NEJM. Confirmou perda de peso superior a semaglutida e tirzepatida em comparações indiretas. Redução de circunferência abdominal de até 14,5 cm.
PubMedFrequently Asked Questions
When will retatrutide be approved?
Eli Lilly is conducting phase 3 studies (TRIUMPH program) with results expected between 2025-2026. FDA submission will likely occur in 2026, with possible approval in 2027. In Brazil, ANVISA approval generally takes an additional 12-18 months after the FDA.
What is the difference between retatrutide, semaglutide, and tirzepatide?
Semaglutide (Ozempic) acts on 1 receptor (GLP-1). Tirzepatide (Mounjaro) acts on 2 receptors (GIP + GLP-1). Retatrutide acts on 3 receptors (GIP + GLP-1 + glucagon). Each additional receptor potentiates the effect: ~16% weight loss with semaglutide, ~21% with tirzepatide, ~24% with retatrutide.
Can I buy retatrutide now?
No. Retatrutide is in the experimental phase and has NOT been approved by any regulatory agency (FDA, ANVISA, EMA). Any product sold as retatrutide is unregulated, has no purity guarantee, and is potentially dangerous. Wait for the completion of clinical trials and regulatory approval.
Are the side effects worse than Ozempic's?
Gastrointestinal effects (nausea, diarrhea, vomiting) appear similar or slightly more frequent than semaglutide in phase 2 studies. The glucagon component may cause a mild increase in heart rate (~2-4 bpm). Gradual titration is essential for tolerability. Long-term safety data are still being collected in phase 3 studies.
Does retatrutide work for type 2 diabetes?
Yes, the results are very promising. In the TRIUMPH-1 study, 78% of patients reached HbA1c < 5.7% (non-diabetic range) at the highest dose. Eli Lilly is developing retatrutide for both obesity and type 2 diabetes.
Important notice
This content is strictly informational and educational, based on published scientific research. It does not constitute medical advice, prescription, or encouragement to use any substance. Always consult a qualified physician before starting any treatment.
Not Yet Available
This compound is still experimental and has not been approved for use. Sign up to be notified when it becomes available.